Search

Your search keyword '"Martínez-Piñeiro L"' showing total 382 results
Start Over Author "Martínez-Piñeiro L"
382 results on '"Martínez-Piñeiro L"'

5. Prevalencia del cáncer del tracto urinario. Análisis de la cohorte española del estudio IDENTIFY

Author

Khadhouri, S., Gallagher, K.M., MacKenzie, K.R., Shah, T.T., Gao, C., Moore, S., Zimmermann, E.F., Edison, E., Jefferies, M., Nambiar, A., Mannas, M.P., Lee, T., Marra, G., Lillaz, B., Gómez Rivas, J., Olivier, J., Assmus, M.A., Uçar, T., Claps, F., Boltri, M., Burnhope, T., Nkwam, N., Tanasescu, G., Boxall, N.E., Downey, A.P., Ahmed Lal, A., Antón-Juanilla, M., Clarke, H., HW Lau, D., Gillams, K., Crockett, M., Nielsen, M., Takwoingi, Y., Chuchu, N., O’Rourke, J., MacLennan, G., McGrath, J.S., Kasivisvanathan, V., Toribio-Vázquez, C., Amigo, F., Carrión, D.M., Yebes, Á., Alonso-Bartolomé, M., Ayllon, H., Aguilera, A., Martinez-Pineiro, L., Crespo-Atín, V., Otaola-Arca, H., Herranz-Yague, J.A., Munoz Rivero, M.V., and Zimmermann, E.

Published
2024
Full Text
View/download PDF

6. Prevalence of urinary tract cancer in the Spanish cohort of the IDENTIFY study

Author

Khadhouri, S., Gallagher, K.M., MacKenzie, K.R., Shah, T.T., Gao, C., Moore, S., Zimmermann, E.F., Edison, E., Jefferies, M., Nambiar, A., Mannas, M.P., Lee, T., Marra, G., Lillaz, B., Rivas, J.G., Olivier, J., Assmus, M.A., Uçar, T., Claps, F., Boltri, M., Burnhope, T., Nkwam, N., Tanasescu, G., Boxall, N.E., Downey, A.P., Lal, A.A., Antón-Juanilla, M., Clarke, H., HW Lau, D., Gillams, K., Crockett, M., Nielsen, M., Takwoingi, Y., Chuchu, N., O’Rourke, J., MacLennan, G., McGrath, J.S., Kasivisvanathan, V., Toribio-Vázquez, C., Gómez Rivas, J., Amigo, F., Carrión, D.M., Yebes, Á., Alonso-Bartolomé, M., Ayllon, H., Aguilera, A., Martinez-Piñeiro, L., Crespo-Atín, V., Otaola-Arca, H., Herranz-Yague, J.A., Munoz Rivero, M.V., and Zimmermann, E.

Published
2024
Full Text
View/download PDF

16. European Association of Urology (@Uroweb) recommendations on the appropriate use of social media

Author

Rouprêt, M, Morgan, TM, Bostrom, PJ, Cooperberg, MR, Kutikov, A, Linton, KD, Palou, J, Martínez-Piñeiro, L, Van Der Poel, H, Wijburg, C, Winterbottom, A, Woo, HH, Wirth, MP, and Catto, JWF

Subjects
Urology & Nephrology, Clinical Sciences
Abstract

Social media use is becoming common in medical practice. Although primarily used in this context to connect physicians, social media allows users share information, to create an online profile, to learn and keep knowledge up to date, to facilitate virtual attendance at medical conferences, and to measure impact within a field. However, shared content should be considered permanent and beyond the control of its author, and typical boundaries, such as the patient-physician interaction, become blurred, putting both parties at risk. The European Association of Urology brought together a committee of stakeholders to create guidance on the good practice and standards of use of social media. These encompass guidance about defining an online profile; managing accounts; protecting the reputations of yourself and your organization; protecting patient confidentiality; and creating honest, responsible content that reflects your standing as a physician and your membership within this profession. © 2014 European Association of Urology.

Published
2014

17. Ensayo clínico aleatorizado: utilización de la luz IMAGE1S (SPIES) vs. luz blanca durante la resección transuretral de tumores vesicales para la prevención de recurrencias, análisis a los 12 meses de seguimiento

Author

Trelles Guzmán, C.R., primary, Linares Espinós, E., additional, Ríos González, E., additional, Alonso Dorrego, J.M., additional, Aguilera Bazán, A., additional, Jiménez Romero, M.E., additional, and Martínez-Piñeiro, L., additional

Published
2023
Full Text
View/download PDF

18. Comparing the use of AquaBeam® and HoLEP for the treatment of patients with benign prostatic hyperplasia

Author

Toribio-Vazquez, C., primary, Cansino, R., additional, Fernández-Pascual, E., additional, Eguibar, A., additional, Ayllon, H., additional, Solano-Heranz, P., additional, Perez-Carral, J.R., additional, Mainez, J.A., additional, Giron, M., additional, Rodriguez, A., additional, Yebes, A., additional, Alonso, M., additional, Martínez, S., additional, and Martínez-Piñeiro, L., additional

Published
2023
Full Text
View/download PDF

19. Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial.

Author

Straten, C.G.J.I. van, Caris, C., Grimm, M.O., Colombel, M., Muilwijk, T., Martínez-Piñeiro, L., Babjuk, M.M., Türkeri, L.N., Palou, J., Patel, Anup, Bjartell, A.S., Witjes, W.P.J., Heijden, A.G. van der, Kiemeney, L.A.L.M., Straten, C.G.J.I. van, Caris, C., Grimm, M.O., Colombel, M., Muilwijk, T., Martínez-Piñeiro, L., Babjuk, M.M., Türkeri, L.N., Palou, J., Patel, Anup, Bjartell, A.S., Witjes, W.P.J., Heijden, A.G. van der, and Kiemeney, L.A.L.M.

Abstract

Item does not contain fulltext, BACKGROUND: Adverse events induced by intravesical bacillus Calmette-Guérin (BCG) to treat high-grade non-muscle-invasive bladder cancer (NMIBC) often lead to treatment discontinuation. The EAU-RF NIMBUS trial found a reduced number of standard-dose BCG instillations to be inferior with the standard regimen. Nonetheless, it remains important to evaluate whether patients in the reduced BCG treatment arm had better quality of life (QoL) due to a possible reduction in toxicity or burden. OBJECTIVE: To evaluate whether patients in the EAU-RF NIMBUS trial experienced better QoL after a reduced BCG instillation frequency. DESIGN SETTING AND PARTICIPANTS: A total of 359 patients from 51 European sites were randomized to one of two treatment arms between December 2013 and July 2019. The standard frequency arm (n = 182) was 6 weeks of BCG induction followed by 3 weeks of maintenance at months 3, 6, and 12. The reduced frequency arm (n = 177) was BCG induction at weeks 1, 2, and 6, followed by maintenance instillations at weeks 1 and 3 of months 3, 6, and 12. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Analyses were performed using an intention-to-treat analysis and a per-protocol analysis. QoL was measured using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 version 3.0 (QLQ-C30 v.03) prior to the first and last instillations of each BCG cycle. Group differences were determined using linear regression corrected for QoL at baseline. Differences in QoL over time were tested for significance using a linear mixed model. Side effects were recorded by the treating physician using a standardized form. Chi-square tests were used to compare the side-effect frequency between the arms. RESULTS AND LIMITATIONS: There were no significant differences in the means of each QoL scale between the two arms. There were also no significant changes over time in all QoL domains for both arms. However, differences in the incidence of

Published
2023

26. Long-term prospective results of the Spanish multicentre experience using recirculant hyperthermic MMC with Combat BRS HIVEC system

Author

Guerrero-Ramos, F., primary, Plata-Bello, A., additional, González-Díaz, A., additional, García, C., additional, González-Valcárcel, I., additional, De La Morena-Gallego, J.M., additional, Díaz-Goizueta, F.J., additional, Fernández-Álamo, J., additional, Gonzalo, V., additional, Montero, J., additional, Sousa-Escandón, A., additional, León, J., additional, Pontones, J.L., additional, Delgado, F., additional, Adriazola, M., additional, Pascual, Á., additional, Calleja, J., additional, Ruano, A., additional, Martínez-Piñeiro, L., additional, and Angulo-Cuesta, J., additional

Published
2022
Full Text
View/download PDF

28. Treatment of EAU intermediate risk category non-muscle invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations. A subgroup analysis of the ‘NIMBUS’ phase III clinical trial

Author

Türkeri, L., primary, Karşıyakalı, N., additional, Grimm, M-O., additional, Van Der Heijden, A.G., additional, Colombel, M., additional, Muilwijk, T., additional, Martínez-Piñeiro, L., additional, Babjuk, M.M., additional, Patel, A., additional, Palou, J., additional, Bjartell, A.S., additional, Caris, C., additional, Schipper, R.G., additional, and Witjes, W.P.J., additional

Published
2021
Full Text
View/download PDF

31. Detection of lymph node metastases using pooling method by One-Step Nucleic Acid Amplification (OSNA) assay in prostate cancer patients: Preliminary results

Author

Cuadras Sole, M., primary, Planas Morin, J., additional, Celma Domènech, A., additional, Regis Plácido, L., additional, Semidey Raven, M.E., additional, De Torres Ramírez, I.M., additional, Ramón, S., additional, Cajal, S., additional, Congregado Ruiz, B., additional, Baena Villamarín, C., additional, Japón Rodrigues, M.Á., additional, De Álava Casado, E., additional, Marcilla Plaza, D., additional, Martínez-Piñeiro, L., additional, Hardisson, D., additional, González-Peramato, P., additional, García Fernández, E., additional, Buisán Rueda, O., additional, Areal Calama, J., additional, Fernández Ruiz, P.L., additional, Carrato Moñino, C., additional, Gómez-Plaza, M.C., additional, Trilla Herrera, E., additional, and Morote Robles, J., additional

Published
2021
Full Text
View/download PDF

32. Zinner Syndrome with Ectopic Ureter Emptying into Seminal Vesicle

Author

Hevia Palacios, M., Álvarez-Maestro, M., Gómez Rivas, J., Aguilera Bazan, A., and Martínez-Piñeiro, L.

Subjects
Article Subject, urologic and male genital diseases
Abstract

A 66-year-old male patient in follow-up in the urology department for a non-muscle-invasive bladder cancer was detected by ultrasound to have absence of the left kidney and a cystic, multilobed image at the location of the seminal vesicle. Magnetic resonance imaging reveals left renal agenesis and the existence of multiple cysts in the ipsilateral seminal vesicle that reaches a size of 6.9×3.7 cm, as well as a ureteral remnant that opens into the seminal vesicle. The patient does not present urinary symptoms, neither pain with ejaculation nor hematuria. A triad of seminal vesicle cyst, ipsilateral renal agenesis, and ipsilateral ejaculatory duct obstruction is known as Zinner syndrome. Congenital anomalies of the seminal vesicles are rare; some of them are associated with malformations of the upper urinary system. Seminal vesicle cysts are associated with ipsilateral renal agenesis and ectopic or dysplastic ureter. Patients may remain asymptomatic and be diagnosed incidentally or may present with symptoms such as increased urinary frequency, dysuria, recurrent infections, pain with ejaculation, and perineal discomfort.

Published
2021
Full Text
View/download PDF

33. Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain

Author

Plata A, Guerrero-Ramos F, Garcia C, González-Díaz A, Gonzalez-Valcárcel I, de la Morena JM, Díaz-Goizueta FJ, Del Álamo JF, Gonzalo V, Montero J, Sousa-Escandón A, León J, Pontones JL, Delgado F, Adriazola M, Pascual Á, Calleja J, Ruano A, Martínez-Piñeiro L, and Angulo JC

Subjects
bladder neoplasia, bladder recirculation system, hyperthermic intravesical chemotherapy, mitomycin-C
Abstract

(1) Background: Intravesical mitomycin-C (MMC) combined with hyperthermia is increasingly used in non-muscle invasive bladder cancer (NMIBC), especially in the context of a relative BCG shortage. We aim to determine real-world data on the long-term treatment outcomes of adjunct hyperthermic intravesical chemotherapy (HIVEC) with MMC and a COMBAT® bladder recirculation system (BRS); (2) Methods: A prospective observational trial was performed on patients with NMIBC treated with HIVEC using BRS in nine academic institutions in Spain between 2012-2020 (HIVEC-E). Treatment effectiveness (recurrence, progression and overall mortality) was evaluated in patients treated with HIVEC MMC 40mg in the adjuvant setting, with baseline data and a clinical follow-up, that comprise the Full Analysis Set (FAS). Safety, according to the number and severity of adverse effects (AEs), was evaluated in the safety (SAF) population, composed by patients with at least one adjunct HIVEC MMC instillation; (3) Results: The FAS population ( n = 502) received a median number of 8.78 ± 3.28 (range 1-20) HIVEC MMC instillations. The median follow-up duration was 24.5 ± 16.5 (range 1-81) months. Its distribution, based on EAU risk stratification, was 297 (59.2%) for intermediate and 205 (40.8%) for high-risk. The figures for five-year recurrence-free and progression-free survival were 50.37% (53.3% for intermediate and 47.14% for high-risk) and 89.83% (94.02% for intermediate and 84.23% for high-risk), respectively. A multivariate analysis identified recurrent tumors (HR 1.83), the duration of adjuvant HIVEC therapy

Published
2021

42. La resonancia magnética como herramienta para el diagnóstico del cáncer de próstata: nuevas evidencias y posicionamiento de la ESUT (EAU Section of Uro-Technology)

Author

Álvarez-Maestro, M., primary, Gómez Rivas, J., additional, Quesada Olarte, J., additional, Carrión, D.M., additional, Trelles Guzman, C., additional, Ballesteros, C., additional, Quintana, L.M., additional, Aguilera Bazán, A., additional, Martínez-Piñeiro, L., additional, Liatsikos, E., additional, and Barret, E., additional

Published
2020
Full Text
View/download PDF

46. Treatment of high grade non-muscle invasive bladder carcinoma by standard number and dose of intravesical BCG instillations versus reduced number and dose of intravesical BCG instillations. An initial report of the phase III clinical trial ‘NIMBUS’

Author

Grimm, M-O., primary, Van Der Heijden, A., additional, Colombel, M., additional, Muilwijk, T., additional, Martínez-Piñeiro, L., additional, Bjartell, A., additional, Caris, C., additional, Schipper, R., additional, Witjes, W., additional, Babjuk, M., additional, and Türkeri, L., additional

Published
2019
Full Text
View/download PDF

49. O6 - Treatment of EAU intermediate risk category non-muscle invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations. A subgroup analysis of the ‘NIMBUS’ phase III clinical trial

Author

Türkeri, L., Karşıyakalı, N., Grimm, M-O., Van Der Heijden, A.G., Colombel, M., Muilwijk, T., Martínez-Piñeiro, L., Babjuk, M.M., Patel, A., Palou, J., Bjartell, A.S., Caris, C., Schipper, R.G., and Witjes, W.P.J.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results